Trans Genic Inc. | Balance Sheet

Fiscal year is April-March. All values JPY Millions.
2014
2015
2016
2017
2018
2019
Cash & Short Term Investments
1,384
1,346
1,054
1,059
1,773
1,278
Total Accounts Receivable
403
451
488
417
625
693
Inventories
70
81
101
155
382
661
Other Current Assets
31
55
76
66
293
271
Total Current Assets
1,888
1,934
1,719
1,697
3,072
2,903
Net Property, Plant & Equipment
1,405
1,407
1,429
1,476
1,509
2,162
Total Investments and Advances
7
7
549
513
668
565
Long-Term Note Receivable
10
9
8
6
3
1
Intangible Assets
235
200
171
131
535
498
Other Assets
19
17
27
38
115
117
Total Assets
3,564
3,574
3,905
3,902
5,935
6,475
ST Debt & Current Portion LT Debt
91
131
74
68
285
Accounts Payable
-
3
25
4
45
Income Tax Payable
6
21
17
46
27
Other Current Liabilities
204
270
380
371
500
Total Current Liabilities
301
424
495
488
856
Long-Term Debt
497
373
324
236
726
Deferred Taxes
-
-
2
41
26
Other Liabilities
-
-
16
5
5
Total Liabilities
799
796
836
729
1,593
Common Equity (Total)
2,713
2,777
3,070
3,173
4,342
Total Shareholders' Equity
2,713
2,777
3,070
3,173
4,342
Total Equity
2,765
2,777
3,070
3,173
4,342
Liabilities & Shareholders' Equity
3,564
3,574
3,905
3,902
5,935
Accumulated Minority Interest
52
-
-
-
-

About Trans Genic

View Profile
Address
ibb Fukuoka, 2/F
Fukuoka Fukuoka 810
Japan
Employees -
Website http://www.transgenic.co.jp
Updated 07/08/2019
Trans Genic Inc. engages in the research and development, distribution, and licensing of genetically engineered animals and antibodies. It operates through the following segments: Genomics, CRO Business, Antibody and Reagent, and Pathological Diagnosis. The Genomics segment conducts contract knockout mouse production, gene analysis service, and sales of disease-model mouse.